One component fibrin glue comprising zymogens
AssigneesOmrix Biopharmaceuticals Ltd., Ethicon, Inc.
InventorsYair PILPEL, Ashley DEANGLIS, Yuri ZHERDEV, Sivan DORON, Anne GORMAN, Israel NUR
Life of this patent
Estimating the term…
Abstract
Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).
Claims14
A sealant formulation comprising fibrinogen;
- vitamin K-dependent clotting zymogens comprising at least Factor II and Factor X;
- and at least one reversible inhibitor of at least one of the vitamin K-dependent clotting zymogens, wherein the formulation is free of an added irreversible thrombin inhibitor.
2-27. (canceled)
34-42. (canceled)
A sealant formulation comprising fibrinogen;
- vitamin K-dependent clotting zymogens comprising at least Factor II, Factor IX and Factor X;
- and at least one reversible inhibitor of at least one of the vitamin K-dependent clotting zymogen, wherein the formulation is free of added irreversible thrombin inhibitor.
A calcium-free sealant formulation comprising fibrinogen and vitamin K-dependent clotting zymogens comprising at least Factor II and Factor X.46. (original) A method for preparing a sealant at a surface comprising:
- providing the formulation of claim 44 or 45;
- and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.
The method of claim 46, wherein the conditions comprise adding a calcium cation.
48-50. (canceled)
Dependencies are inferred from the claim text.